{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Thera+Tears",
    "query": {
      "intervention": "Thera Tears"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 98,
    "total_pages": 10,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Thera+Tears&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-11T04:43:14.148Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02951052",
      "title": "Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Cabotegravir (CAB) tablet",
          "type": "DRUG"
        },
        {
          "name": "Rilpivirine (RPV) tablet",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir - Injectable Suspension (CAB LA)",
          "type": "DRUG"
        },
        {
          "name": "Rilpivirine - Injectable Suspension (RPV LA)",
          "type": "DRUG"
        },
        {
          "name": "2 NRTIs plus an INI, NNRTI, or PI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 618,
      "start_date": "2016-10-28",
      "completion_date": "2029-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-09-11T04:43:14.148Z",
      "location_count": 36,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02951052"
    },
    {
      "nct_id": "NCT01299662",
      "title": "Polyinosinic-Polycytidylic Acid-poly-L-lysine Carboxymethylcellulose (Poly-ICLC) in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Poly ICLC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rockefeller University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 6,
      "start_date": "2011-06",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2012-08-13",
      "last_synced_at": "2026-09-11T04:43:14.148Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01299662"
    },
    {
      "nct_id": "NCT01072357",
      "title": "Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Corneal Neovascularization",
        "Corneal Graft Failure"
      ],
      "interventions": [
        {
          "name": "Avastin® (bevacizumab)",
          "type": "DRUG"
        },
        {
          "name": "0.9% NaCl & Refresh Liquigel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Reza Dana, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2009-12",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2018-06-15",
      "last_synced_at": "2026-09-11T04:43:14.148Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01072357"
    },
    {
      "nct_id": "NCT03358719",
      "title": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Blasts 30 Percent or Less of Bone Marrow Nucleated Cells",
        "Chronic Myelomonocytic Leukemia",
        "High Risk Myelodysplastic Syndrome",
        "Myelodysplastic Syndrome",
        "Refractory Anemia"
      ],
      "interventions": [
        {
          "name": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Poly ICLC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2018-03-27",
      "completion_date": "2021-08-25",
      "has_results": true,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-09-11T04:43:14.148Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03358719"
    },
    {
      "nct_id": "NCT06472661",
      "title": "FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Advanced Melanoma"
      ],
      "interventions": [
        {
          "name": "Echopulse or Echopulse HD",
          "type": "DEVICE"
        },
        {
          "name": "PolyICLC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2024-09-27",
      "completion_date": "2026-08",
      "has_results": false,
      "last_update_posted_date": "2025-11-20",
      "last_synced_at": "2026-09-11T04:43:14.148Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06472661"
    },
    {
      "nct_id": "NCT02544529",
      "title": "Echothiophate Iodide for the Prevention of Progression of Myopia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Myopia"
      ],
      "interventions": [
        {
          "name": "Echothiophate Iodide 0.03% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Carboxymethylcellulose Sodium (0.5%)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Danbury Eye Physicians & Surgeons, PC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "15 Years",
        "sex": "ALL",
        "summary": "9 Years to 15 Years"
      },
      "enrollment_count": 0,
      "start_date": "2016-06-01",
      "completion_date": "2016-06-01",
      "has_results": false,
      "last_update_posted_date": "2025-02-07",
      "last_synced_at": "2026-09-11T04:43:14.148Z",
      "location_count": 1,
      "location_summary": "Danbury, Connecticut",
      "locations": [
        {
          "city": "Danbury",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02544529"
    },
    {
      "nct_id": "NCT00756678",
      "title": "Efficacy and Acceptability of Two Lubricant Eye Drops",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dry Eye Syndromes"
      ],
      "interventions": [
        {
          "name": "Lubricant Eye Drops (Optive™)",
          "type": "DRUG"
        },
        {
          "name": "Lubricating Eye Drops (blink® Tears)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2008-09",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2011-10-31",
      "last_synced_at": "2026-09-11T04:43:14.148Z",
      "location_count": 1,
      "location_summary": "Chevy Chase, Maryland",
      "locations": [
        {
          "city": "Chevy Chase",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00756678"
    },
    {
      "nct_id": "NCT00691197",
      "title": "Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Ametropia"
      ],
      "interventions": [
        {
          "name": "Carboxymethylcellulose sodium and Glycerin",
          "type": "DEVICE"
        },
        {
          "name": "Carboxymethylcellulose sodium",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 246,
      "start_date": "2008-03",
      "completion_date": "2008-10",
      "has_results": true,
      "last_update_posted_date": "2015-07-22",
      "last_synced_at": "2026-09-11T04:43:14.148Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00691197"
    },
    {
      "nct_id": "NCT02938520",
      "title": "Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Cabotegravir (CAB) tablet",
          "type": "DRUG"
        },
        {
          "name": "Rilpivirine (RPV) tablet",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir - Injectable Suspension (CAB LA)",
          "type": "DRUG"
        },
        {
          "name": "Rilpivirine - Injectable Suspension (RPV LA)",
          "type": "DRUG"
        },
        {
          "name": "ABC/DTG/3TC STR - Tablet",
          "type": "DRUG"
        },
        {
          "name": "DTG Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 631,
      "start_date": "2016-10-27",
      "completion_date": "2029-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-09-11T04:43:14.148Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02938520"
    },
    {
      "nct_id": "NCT03918590",
      "title": "Post Intravitreal Injection Topical NSAID vs. Patching",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration",
        "Diabetic Macular Edema",
        "Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)",
          "type": "DRUG"
        },
        {
          "name": "Theratears tear drop, (Akron, Ann 111 Arbor, MI)",
          "type": "DRUG"
        },
        {
          "name": "patching",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "The New York Eye & Ear Infirmary",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2018-12-03",
      "completion_date": "2019-06-03",
      "has_results": false,
      "last_update_posted_date": "2019-04-17",
      "last_synced_at": "2026-09-11T04:43:14.148Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03918590"
    }
  ]
}